Journal Article
. 2014 Jun;32(20).
doi: 10.1200/JCO.2013.53.1608.

Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study

Ines Vaz-Luis 1 Rebecca A Ottesen 1 Melissa E Hughes 1 Rizvan Mamet 1 Harold J Burstein 1 Stephen B Edge 1 Ana M Gonzalez-Angulo 1 Beverly Moy 1 Hope S Rugo 1 Richard L Theriault 1 Jane C Weeks 1 Eric P Winer 1 Nancy U Lin 2 
Affiliations
  • PMID: 24888816
  •     45 References
  •     56 citations

Abstract

Purpose: Treatment decisions for patients with T1a,bN0M0 breast cancer are challenging. We studied the time trends in use of adjuvant chemotherapy and survival outcomes among these patients.

Patients And Methods: This was a prospective cohort study within the National Comprehensive Cancer Network Database that included 4,113 women with T1a,bN0M0 breast cancer treated between 2000 and 2009. Tumors were grouped by size (T1a, T1b), biologic subtype defined by hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status, and receipt of chemotherapy with or without trastuzumab.

Results: Median follow-up time was 5.5 years. Eight percent of patients with HR-positive/HER2-negative tumors were treated with chemotherapy. Fifty-two percent of those with HER2-positive or HR-negative/HER2-negative breast cancers received chemotherapy, with an increase over the last decade. Survival outcomes diverged by subtype and size, but the 5-year distant relapse-free survival (DRFS) did not exceed 10% in any subgroup. The 5-year DRFS for patients with T1a tumors untreated with chemotherapy ranged from 93% to 98% (n = 49 to 972), and for patients with T1b tumors, it ranged from 90% to 96% (n = 17 to 2,005). Patients with HR-positive/HER2-negative disease had the best DRFS estimates, and patients with HR-negative/HER2-negative tumors had the lowest. In this observational, nonrandomized cohort study, the 5-year DRFS for treated patients with T1a tumors was 100% for all subgroups (n = 12 to 33), and for patients with T1b tumors, it ranged from 94% to 96% (n = 88 to 241).

Conclusion: Women with T1a,b tumors have an excellent prognosis without chemotherapy. Size and tumor subtype may identify patients in whom the rate of recurrence justifies consideration of chemotherapy. These patients represent an optimal group for evaluating less toxic adjuvant regimens to maintain efficacy while minimizing short- and long-term risks.

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Clifford A Hudis, William E Barlow, +8 authors, Jo Anne Zujewski.
J Clin Oncol, 2007 May 22; 25(15). PMID: 17513820
Highly Cited.
Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
Louis Fehrenbacher, Angela M Capra, +3 authors, Laurel A Habel.
J Clin Oncol, 2014 Jun 04; 32(20). PMID: 24888815
NCCN outcomes research database: data collection via the Internet.
J C Niland.
Oncology (Williston Park), 2001 Feb 24; 14(11A). PMID: 11195402
Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
B Fisher, J Dignam, +4 authors, N Wolmark.
J Natl Cancer Inst, 2001 Feb 24; 93(2). PMID: 11208880
The full potential of breast cancer screening use to reduce mortality has not yet been realized in the United States.
Mario Schootman, Donna Jeffe, Anat Reschke, Rebecca Aft.
Breast Cancer Res Treat, 2004 Apr 28; 85(3). PMID: 15111759
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
M E Charlson, P Pompei, K L Ales, C R MacKenzie.
J Chronic Dis, 1987 Jan 01; 40(5). PMID: 3558716
Highly Cited.
A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma.
P R Rosen, S Groshen, +2 authors, S Hellman.
J Clin Oncol, 1989 Mar 01; 7(3). PMID: 2918331
Highly Cited.
Breast cancer treatment and natural history: new insights from results of screening.
L Tabár, G Fagerberg, +2 authors, R M Kitchin.
Lancet, 1992 Feb 15; 339(8790). PMID: 1346670
Insights into breast cancer screening of younger women. Evidence from the 14-year follow-up of the Breast Cancer Detection Demonstration Project.
C R Smart, W H Hartmann, O H Beahrs, L Garfinkel.
Cancer, 1993 Aug 15; 72(4 Suppl). PMID: 8339237
Paclitaxel-induced neuropathy.
T J Postma, J B Vermorken, +2 authors, J J Heimans.
Ann Oncol, 1995 May 01; 6(5). PMID: 7669713
Can comorbidity be measured by questionnaire rather than medical record review?
J N Katz, L C Chang, +2 authors, D W Bates.
Med Care, 1996 Jan 01; 34(1). PMID: 8551813
Highly Cited.
Outcomes assessment in the NCCN.
J C Weeks.
Oncology (Williston Park), 1998 Jan 16; 11(11A). PMID: 9430183
Outcomes assessment in the NCCN: 1998 update. National Comprehensive Cancer Network.
J Weeks.
Oncology (Williston Park), 1999 Jun 17; 13(5A). PMID: 10370922
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
The effect of tissue fixation and processing on breast cancer size.
Bobbi Pritt, Joseph J Tessitore, Donald L Weaver, Hagen Blaszyk.
Hum Pathol, 2005 Aug 09; 36(7). PMID: 16084944
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Martine J Piccart-Gebhart, Marion Procter, +30 authors, Herceptin Adjuvant (HERA) Trial Study Team.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236737
Highly Cited.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Edward H Romond, Edith A Perez, +22 authors, Norman Wolmark.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236738
Highly Cited.
Effect of screening and adjuvant therapy on mortality from breast cancer.
Donald A Berry, Kathleen A Cronin, +8 authors, Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators.
N Engl J Med, 2005 Oct 28; 353(17). PMID: 16251534
Highly Cited.
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, +22 authors, FinHer Study Investigators.
N Engl J Med, 2006 Feb 24; 354(8). PMID: 16495393
Highly Cited.
Peripheral neuropathy induced by microtubule-stabilizing agents.
James J Lee, Sandra M Swain.
J Clin Oncol, 2006 Apr 01; 24(10). PMID: 16575015
Highly Cited. Review.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.
Michael J Hassett, A James O'Malley, +2 authors, Craig C Earle.
J Natl Cancer Inst, 2006 Aug 17; 98(16). PMID: 16912263
Highly Cited.
Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.
Ines Vaz-Luis, Rebecca A Ottesen, +8 authors, Nancy U Lin.
Breast Cancer Res, 2012 Oct 03; 14(5). PMID: 23025714    Free PMC article.
Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients.
Timothy Kennedy, Andrew K Stewart, +3 authors, David P Winchester.
Ann Surg Oncol, 2007 Jul 20; 14(10). PMID: 17638060
Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.
Emer O Hanrahan, Ana M Gonzalez-Angulo, +4 authors, Vicente Valero.
J Clin Oncol, 2007 Nov 01; 25(31). PMID: 17971593
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
M Untch, R D Gelber, +26 authors, HERA Study Team.
Ann Oncol, 2008 Feb 26; 19(6). PMID: 18296421
Factors associated with guideline-concordant use of radiotherapy after mastectomy in the national comprehensive cancer network.
Rinaa S Punglia, Melissa E Hughes, +6 authors, Jane C Weeks.
Int J Radiat Oncol Biol Phys, 2008 May 13; 72(5). PMID: 18472360    Free PMC article.
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
Stephen Chia, Brian Norris, +7 authors, Karen Gelmon.
J Clin Oncol, 2008 Nov 13; 26(35). PMID: 19001334
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
Ana M Gonzalez-Angulo, Jennifer K Litton, +17 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2009 Nov 04; 27(34). PMID: 19884543    Free PMC article.
Highly Cited.
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.
Giuseppe Curigliano, Giuseppe Viale, +10 authors, Aron Goldhirsch.
J Clin Oncol, 2009 Nov 04; 27(34). PMID: 19884553
A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?
Yeon Hee Park, Seung Tae Kim, +11 authors, Young-Hyuck Im.
Breast Cancer Res Treat, 2009 Dec 04; 119(3). PMID: 19957028
Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.
Lesley A Smith, Victoria R Cornelius, +4 authors, Alison Jones.
BMC Cancer, 2010 Jul 01; 10. PMID: 20587042    Free PMC article.
Highly Cited. Systematic Review.
Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status.
Surabhi Amar, Ann E McCullough, +7 authors, Edith A Perez.
Oncologist, 2010 Oct 12; 15(10). PMID: 20930097    Free PMC article.
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
Edith A Perez, Edward H Romond, +7 authors, Norman Wolmark.
J Clin Oncol, 2011 Jul 20; 29(25). PMID: 21768458    Free PMC article.
Highly Cited.
Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis Slamon, Wolfgang Eiermann, +21 authors, Breast Cancer International Research Group.
N Engl J Med, 2011 Oct 14; 365(14). PMID: 21991949    Free PMC article.
Highly Cited.
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
Heather L McArthur, Kathleen M Mahoney, +5 authors, Clifford A Hudis.
Cancer, 2011 Jun 18; 117(24). PMID: 21681735
Implications of HER2 amplification in small, node-negative breast cancers: do Asians differ?
Fuh Yong Wong, Connie Siew Poh Yip, Eu Tiong Chua.
World J Surg, 2011 Nov 23; 36(2). PMID: 22105650
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
Erin J Aiello Bowles, Robert Wellman, +13 authors, Pharmacovigilance Study Team.
J Natl Cancer Inst, 2012 Sep 06; 104(17). PMID: 22949432    Free PMC article.
Highly Cited.
Does breast cancer tumor size really matter that much?
Louise Provencher, Caroline Diorio, +2 authors, Simon Jacob.
Breast, 2012 Jul 28; 21(5). PMID: 22835917
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
Edward H Romond, Jong-Hyeon Jeong, +18 authors, Norman Wolmark.
J Clin Oncol, 2012 Sep 19; 30(31). PMID: 22987084    Free PMC article.
Highly Cited.
Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
Jersey Chen, Jessica B Long, +3 authors, Cary P Gross.
J Am Coll Cardiol, 2012 Nov 20; 60(24). PMID: 23158536
Highly Cited.
Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.
Lindsay M Morton, Graça M Dores, +5 authors, Rochelle E Curtis.
Blood, 2013 Feb 16; 121(15). PMID: 23412096    Free PMC article.
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Sandra M Swain, Gong Tang, +17 authors, Norman Wolmark.
J Clin Oncol, 2013 Aug 14; 31(26). PMID: 23940225    Free PMC article.
Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study.
Ines Vaz-Luis, Nancy L Keating, +3 authors, Rachel A Freedman.
J Clin Oncol, 2014 Feb 12; 32(9). PMID: 24516021    Free PMC article.
Update on adjuvant chemotherapy for early breast cancer.
Murtuza M Rampurwala, Gabrielle B Rocque, Mark E Burkard.
Breast Cancer (Auckl), 2014 Oct 23; 8. PMID: 25336961    Free PMC article.
Review.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Sara M Tolaney, William T Barry, +16 authors, Eric P Winer.
N Engl J Med, 2015 Jan 08; 372(2). PMID: 25564897    Free PMC article.
Highly Cited.
[Is the waiver of chemotherapy for small, node-negative breast cancer justified? ].
Marie-Luise Sautter-Bihl, Felix Sedlmayer.
Strahlenther Onkol, 2015 Mar 03; 191(1). PMID: 25729794
Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study.
Ines Vaz-Luis, Melissa E Hughes, +7 authors, Nancy U Lin.
Cancer, 2015 Mar 12; 121(12). PMID: 25757412    Free PMC article.
Treatment of early-stage HER2+ breast cancer-an evolving field.
Arlindo R Ferreira, Kamal S Saini, Otto Metzger-Filho.
Ecancermedicalscience, 2015 May 02; 9. PMID: 25932047    Free PMC article.
Review.
Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.
Ciara C O'Sullivan, Ian Bradbury, +13 authors, Richard D Gelber.
J Clin Oncol, 2015 Jun 24; 33(24). PMID: 26101239    Free PMC article.
Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer.
Catherine L Forse, Seema Agarwal, +9 authors, Irene L Andrulis.
BMC Cancer, 2015 Jun 27; 15. PMID: 26112005    Free PMC article.
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.
Stefania Gori, Alessandro Inno, +33 authors, Luca Boni.
PLoS One, 2015 Sep 05; 10(9). PMID: 26340098    Free PMC article.
SEOM clinical guidelines in early-stage breast cancer 2015.
J A Garcia-Saenz, B Bermejo, +7 authors, E Ciruelos.
Clin Transl Oncol, 2015 Oct 27; 17(12). PMID: 26497356    Free PMC article.
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Chau Dang, Hao Guo, +17 authors, Sara M Tolaney.
JAMA Oncol, 2015 Nov 06; 2(1). PMID: 26539793    Free PMC article.
Infracentimetric HER-2 positive breast tumours-review of the literature.
Danilo da Fonseca Reis Silva, Joana M Ribeiro.
Ecancermedicalscience, 2015 Dec 05; 9. PMID: 26635897    Free PMC article.
Review.
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shaokun Shu, Charles Y Lin, +36 authors, Kornelia Polyak.
Nature, 2016 Jan 07; 529(7586). PMID: 26735014    Free PMC article.
Highly Cited.
Biologic subtype is a more important prognostic factor than nodal involvement in patients with stages I and II breast carcinoma.
Hyosun Kim, Jihyoung Cho, Sun Young Kwon, Sun Hee Kang.
Ann Surg Treat Res, 2016 Jan 23; 90(1). PMID: 26793686    Free PMC article.
Toward precision medicine of breast cancer.
Nicolas Carels, Lizânia Borges Spinassé, Tatiana Martins Tilli, Jack Adam Tuszynski.
Theor Biol Med Model, 2016 Mar 02; 13. PMID: 26925829    Free PMC article.
Review.
Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer.
Katherine Reeder-Hayes, Sharon Peacock Hinton, +2 authors, Stacie B Dusetzina.
J Clin Oncol, 2016 Apr 14; 34(17). PMID: 27069085    Free PMC article.
Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.
Andrew J Robles, Shengxin Cai, Robert H Cichewicz, Susan L Mooberry.
Breast Cancer Res Treat, 2016 Jun 04; 157(3). PMID: 27255535    Free PMC article.
Maximiscin Induces DNA Damage, Activates DNA Damage Response Pathways, and Has Selective Cytotoxic Activity against a Subtype of Triple-Negative Breast Cancer.
Andrew J Robles, Lin Du, Robert H Cichewicz, Susan L Mooberry.
J Nat Prod, 2016 Jun 17; 79(7). PMID: 27310425    Free PMC article.
Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion.
Yan Fang, Jiayi Wu, +9 authors, Li Zhu.
Oncotarget, 2016 Sep 01; 7(39). PMID: 27577080    Free PMC article.
Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Karen A Cadoo, Patrick G Morris, +3 authors, Heather L McArthur.
Clin Breast Cancer, 2016 Sep 14; 16(6). PMID: 27622751    Free PMC article.
The impact of doctor-patient communication on patients' perceptions of their risk of breast cancer recurrence.
Nancy K Janz, Yun Li, +7 authors, Sarah T Hawley.
Breast Cancer Res Treat, 2016 Dec 13; 161(3). PMID: 27943007    Free PMC article.
Recurrence risk perception and quality of life following treatment of breast cancer.
Sarah T Hawley, Nancy K Janz, +8 authors, Steven J Katz.
Breast Cancer Res Treat, 2016 Dec 23; 161(3). PMID: 28004220    Free PMC article.
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017).
Michael Untch, Jens Huober, +18 authors, Cornelia Liedtke.
Geburtshilfe Frauenheilkd, 2017 Aug 05; 77(6). PMID: 28769126    Free PMC article.
Impact of Detection Method and Accompanying Ductal Carcinoma in Situ on Prognosis of T1a,bN0 Breast Cancer.
Shih-Che Shen, Shir-Hwa Ueng, +5 authors, Shin-Cheh Chen.
J Cancer, 2017 Aug 19; 8(12). PMID: 28819437    Free PMC article.
Clinicopathological features and survival of early stage breast cancer in northwest China: A population-based retrospective study of 1287 patients.
Shuting Li, Xiangtang Wang, +12 authors, Jin Yang.
Thorac Cancer, 2017 Oct 05; 9(1). PMID: 28976077    Free PMC article.
Structure-Activity Relationships of New Natural Product-Based Diaryloxazoles with Selective Activity against Androgen Receptor-Positive Breast Cancer Cells.
Andrew J Robles, Shelby McCowen, +5 authors, Susan L Mooberry.
J Med Chem, 2017 Oct 21; 60(22). PMID: 29053266    Free PMC article.
Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis.
Xu Liu, Jing-Kun Qu, +7 authors, Xiao-Yi Duan.
Medicine (Baltimore), 2017 Nov 16; 96(45). PMID: 29137007    Free PMC article.
Exogenous reproductive hormone use in breast cancer survivors and previvors.
Ines Vaz-Luis, Ann H Partridge.
Nat Rev Clin Oncol, 2018 Jan 24; 15(4). PMID: 29358778
Review.
The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer.
Seung Taek Lim, Chan Heun Park, +7 authors, Young Jin Suh.
PLoS One, 2018 May 17; 13(5). PMID: 29768496    Free PMC article.
Accuracy of a nomogram to predict the survival benefit of surgical axillary staging in T1 breast cancer patients.
Yuxia Chen, Yuanqi Zhang, +4 authors, Xiang Chen.
Medicine (Baltimore), 2018 Jun 29; 97(26). PMID: 29953003    Free PMC article.
KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer.
Wenyu Wang, Gokce Oguz, +5 authors, Qiang Yu.
J Exp Med, 2018 Sep 30; 215(11). PMID: 30266800    Free PMC article.
Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer?
Changjun Wang, Yidong Zhou, +9 authors, Qiang Sun.
Cancer Med, 2018 Oct 03; 7(11). PMID: 30277006    Free PMC article.
Comprehensive identification and characterization of somatic copy number alterations in triple‑negative breast cancer.
Zaibing Li, Xiao Zhang, +6 authors, Ning Huang.
Int J Oncol, 2020 Jan 03; 56(2). PMID: 31894314    Free PMC article.
Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach.
Belén P Solans, Ascensión López-Díaz de Cerio, +7 authors, Marta Santisteban.
Br J Clin Pharmacol, 2019 Apr 02; 85(8). PMID: 30933365    Free PMC article.
Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer.
Ali Hajjar, Mehmet A Ergun, Oguzhan Alagoz, Murtuza Rampurwala.
PLoS One, 2019 Jun 06; 14(6). PMID: 31166995    Free PMC article.
Regulation of Hippo signaling and triple negative breast cancer progression by an ubiquitin ligase RNF187.
Zhonghao Wang, Qiong Kong, +20 authors, Ting Zhuang.
Oncogenesis, 2020 Mar 22; 9(3). PMID: 32198343    Free PMC article.
Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?
Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen.
Front Oncol, 2020 Jun 02; 10. PMID: 32477946    Free PMC article.
Association of Endocrine Therapy With Overall Survival in Women With Small, Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.
Sung Jun Ma, Oluwadamilola T Oladeru, Anurag K Singh.
JAMA Netw Open, 2020 Aug 25; 3(8). PMID: 32833014    Free PMC article.
Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer.
Bo Chen, Hailin Tang, +4 authors, Ning Liao.
Cancer Manag Res, 2019 Jan 08; 11. PMID: 30613165    Free PMC article.
Construction of prognostic microRNA signature for human invasive breast cancer by integrated analysis.
Wei Shi, Fang Dong, +7 authors, Tao Huang.
Onco Targets Ther, 2019 Apr 03; 12. PMID: 30936717    Free PMC article.
Association of Adjuvant Chemotherapy With Overall Survival Among Women With Small, Node-Negative, Triple-Negative Breast Cancer.
Oluwadamilola T Oladeru, Anurag K Singh, Sung Jun Ma.
JAMA Netw Open, 2020 Sep 15; 3(9). PMID: 32926113    Free PMC article.
Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer.
Jinhong Shi, Feiqi Liu, Yanqiu Song.
Cancer Manag Res, 2020 Oct 17; 12. PMID: 33061626    Free PMC article.
Review.
Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach.
Jennifer Y Sheng, Cesar A Santa-Maria, +18 authors, Karen L Smith.
JCO Oncol Pract, 2020 Jul 01; 16(10). PMID: 32603252    Free PMC article.
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gagan K Gupta, Amber L Collier, +13 authors, Amy H Tang.
Cancers (Basel), 2020 Aug 28; 12(9). PMID: 32846967    Free PMC article.
Review.
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Sara M Tolaney, Hao Guo, +23 authors, Eric P Winer.
J Clin Oncol, 2019 Apr 03; 37(22). PMID: 30939096    Free PMC article.
Highly Cited.
The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy.
Wen-Fen Fu, Qing-Xia Chen, +2 authors, Chuan-Gui Song.
Front Oncol, 2020 Oct 27; 10. PMID: 33102205    Free PMC article.
The ubiquitin ligase RNF181 stabilizes ERα and modulates breast cancer progression.
Jian Zhu, Xin Li, +3 authors, Yinlu Ding.
Oncogene, 2020 Sep 26; 39(44). PMID: 32973333    Free PMC article.
Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer.
Zhen Zhai, Yi Zheng, +12 authors, Zhijun Dai.
JAMA Netw Open, 2020 Nov 20; 3(11). PMID: 33211105    Free PMC article.
Omitting Adjuvant Radiotherapy for Hormone Receptor‒Positive Early-Stage Breast Cancer in Old Age: A Propensity Score Matched SEER Analysis.
Yi-Jun Kim, Kyung Hwan Shin, Kyubo Kim.
Cancer Res Treat, 2018 May 12; 51(1). PMID: 29747486    Free PMC article.
SEOM clinical guidelines in early stage breast cancer (2018).
F Ayala de la Peña, R Andrés, +7 authors, E Ciruelos.
Clin Transl Oncol, 2018 Nov 18; 21(1). PMID: 30443868    Free PMC article.
TRIM3 inhibits P53 signaling in breast cancer cells.
Xinxing Wang, Yujie Zhang, +4 authors, Dongwei Dou.
Cancer Cell Int, 2020 Dec 10; 20(1). PMID: 33292295    Free PMC article.
Multiple Microinvasion Foci in Ductal Carcinoma In Situ Is Associated With an Increased Risk of Recurrence and Worse Survival Outcome.
Jing Si, Rong Guo, +7 authors, Caiping Chen.
Front Oncol, 2020 Dec 22; 10. PMID: 33344258    Free PMC article.
Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis.
Jingyi Zhang, Wenna Wang, +5 authors, Ying Fan.
J Oncol, 2021 Jan 01; 2020. PMID: 33381180    Free PMC article.
Clinical significance of HER2 status in T1bN0 breast cancer: a nationwide study from the Korean Breast Cancer Society.
Young-Joon Kang, Se Jeong Oh, +9 authors, Yong-Seok Kim.
Breast Cancer Res Treat, 2021 Jan 04;. PMID: 33389401
The role of chemotherapy in patients with T1bN0M0 triple-negative breast cancer: a real-world competing risk analysis.
Tian Lan, Yunyan Lu, +4 authors, Zujian Hu.
J Cancer, 2021 Jan 05; 12(1). PMID: 33391398    Free PMC article.
Long-Term Prognostication for 20 114 Women With Small and Node-Negative Breast Cancer (T1abN0).
David Jaraj, Jonas Höijer, +9 authors, Pettersson Andreas.
JNCI Cancer Spectr, 2021 Jan 15; 5(1). PMID: 33442658    Free PMC article.
De-escalated Therapy Omitting Anthracyclines for Stage I HER2-positive Breast Cancer: A Retrospective Observational Study.
Shogo Nakamoto, Masahiko Ikeda, +2 authors, Tetsumasa Yamashita.
In Vivo, 2020 Nov 05; 34(6). PMID: 33144488    Free PMC article.